| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US9522881 |
| Title |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) |
| Abstract |
Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2. |
| Applicant(s) |
Indiana University Research and Technology Corporation |
| Representative Drug(s) |
D0I2AN |
Drug Info
|
IC50 = 1440 nM |
[1] |
| Patent ID |
US8987474 |
| Title |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs |
| Abstract |
Compounds and associated methods for inhibiting a protein tyrosine phosphatase. By a combination of experimental and virtual screenings of the NCI Diversity Set chemical library, NSC-87877 and NSC-117199 have been identified as Shp2 PTP inhibitors. Significantly, NSC-87877 is active in cell-based assays and has no detectable off-target effects in the EGF-stimulated Erk 1/2 activation pathway. Additionally, a number of analogs of NSC-117199 have been produced. These analogs exhibit enhanced protein tyrosine phosphatase inhibition and are found to be potent and/or selective inhibitors of Shp1 and/or Shp2 protein tyrosine phosphatases. |
| Applicant(s) |
University of South Florida; H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| Representative Drug(s) |
D00MFW |
Drug Info
|
N.A. |
[2] |
